Since the response rates to ICB are quite low for advanced NSCLC in unselected subjects to some degree (5, 6), substantial effort is necessary to be invested in finding mechanism-based predictive biomarkers to identify the patients who will respond best to PD-1/PD-L1 pathway inhibition. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.